Live from ClinicalTrials.gov + Open Targets, fetched 2026-11-12 04:02 UTC. Every row links to its source record.
Postmortem · what the sponsor and named sources said, kept apart from what merely happened at the same time
Natalizumab Subcutaneous Immunogenicity and Safety Study
NCT02142192 · Biogen · PHASE2 · terminated · last registry update 2024-06-03 · Decision brief
No research has been run for this trial yet, so only the registry's own reason and the timeline are shown.
What was said, and by whom
Stated is the sponsor's own words; Reported is a named third party. The category is our label from a fixed list; the quote is the evidence.
| Kind | Quote | Our category | Source |
|---|---|---|---|
| Stated | “Sponsor's decision.” | – | Registry record, Biogen |
Also happening at the time. Not shown to be a cause.
Registry events on other trials of drugs against ITGA4 within 12 months either side of this trial's last update, live from ClinicalTrials.gov. Nothing here was stated as a reason.
- 2025-04-03Results posted on the registry: Takeda, Vedolizumab SC (NCT02620046)
- 2025-04-02Results posted on the registry: University of Wisconsin, Madison, Shingrix (NCT03798691)
- 2025-03-18Phase 3 first posted: AbbVie, Risankizumab + Risankizumab (NCT06880744)
- 2025-02-12Results posted on the registry: Takeda, Vedolizumab IV (NCT04804540)
- 2025-01-22Results posted on the registry: State University of New York at Buffalo, Natalizumab (NCT03046251)
- 2025-01-15Also stopped (withdrawn): Case Comprehensive Cancer Center, Natalizumab (NCT03811886)
- 2025-01-01Phase 3 first posted: Federal Research Institute of Pediatric Hematology, Oncology and Immunology, Conditioning regimen: Treosulfan 42 g/m2/course or total body irradiation 12 Gray/course, Etoposide 60 mg/kg , Fludarabine 150 (NCT06756152)
- 2024-09-26Phase 3 first posted: JAROSLAW KIERKUS, Infliximab (NCT06614387)
- 2024-08-26Phase 3 first posted: Alvotech Swiss AG, AVT16 + Vedolizumab (NCT06570772)
- 2024-06-26Phase 3 first posted: Federal Research Institute of Pediatric Hematology, Oncology and Immunology, Baricitinib (NCT06475820)
- 2024-06-21Also stopped (terminated): Biogen, Natalizumab (NCT05532163)
- 2024-06-12Results posted on the registry: Biogen, Natalizumab + Natalizumab (NCT03689972)
- 2024-06-05Phase 3 first posted: Takeda, Vedolizumab + Concomitant Antibiotic Therapy (NCT06443502)
- 2024-06-03Also stopped (withdrawn): Biogen, TYSABRI and AVONEX (NCT00771043)
- 2024-05-08Phase 3 first posted: Takeda, Vedolizumab SC (NCT06405087)
- 2024-04-18Results posted on the registry: Vanderbilt University Medical Center, Natalizumab 300 MG in 15 ML Injection (NCT05177718)
- 2024-04-18Also stopped (terminated): Vanderbilt University Medical Center, Natalizumab 300 MG in 15 ML Injection (NCT05177718)
- 2024-04-10Also stopped (terminated): Centre Hospitalier Universitaire de Saint Etienne, Valganciclovir (NCT04064697)
- 2024-03-29Phase 3 first posted: AHS Cancer Control Alberta, Vedolizumab + Placebo (NCT06337695)
- 2024-03-05Also stopped (terminated): Millennium Pharmaceuticals, Inc., TAK-580 + TAK-202 (NCT02723006)
- 2024-01-29Phase 3 first posted: Takeda, Vedolizumab + Upadacitinib (NCT06227910)
- 2023-11-18Results posted on the registry: Takeda, Vedolizumab (NCT02743806)
- 2023-11-18Also stopped (terminated): Takeda, Vedolizumab (NCT02743806)
- 2023-10-25Phase 3 first posted: Takeda, Vedolizumab IV + Vedolizumab SC (NCT06100289)
- 2023-07-03Results posted on the registry: Polpharma Biologics S.A., Intravenous (IV) infusions (NCT04115488)
What is not public
- Internal portfolio and board discussions
- Unpublished trial data and interim analyses
- Terms of any partner or licence decision